AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

June 8, 2018 — In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression

Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

June 5, 2018 – In SELECT-EARLY, upadacitinib monotherapy (15/30 mg, once-daily) met both primary endpoints, with 52/56 percent of methotrexate-naïve patients achieving ACR50 at week 12 and 48/50 percent achieving clinical remission at week 24, respectively(1) – Both doses of upadacitinib

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma

June 1, 2018 Phase 3 data featured as oral presentation (abstract #8003), selected for Best of ASCO 2018 Meetings, and simultaneously published in The New England Journal of Medicine Study represents first randomized double-blind placebo-controlled trial evaluating treatment-naïve Waldenström’s macroglobulinemia

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

May 24, 2018 Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC) Full study

AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting

MAY 16, 2018 – More than 30 abstracts accepted across hematologic malignancies, solid tumors and other oncology-related diseases – Studies evaluating ibrutinib and venetoclax across various blood cancers, including the CAPTIVATE study in first-line chronic lymphocytic leukemia (CLL) will be presented

AbbVie to Present at the UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 8, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 22, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7:30 a.m. Central time. A

AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

NORTH CHICAGO, Ill., May 2, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 2018 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018. Richard A. Gonzalez, chairman and chief executive officer, will present at 6:20 p.m.

AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock

NORTH CHICAGO, Ill., May 1, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that it has commenced a modified “Dutch auction” tender offer to purchase for cash up to $7.5 billion of its common stock at a price not less than $99.00 per share and not more

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

– Application supported by four pivotal Phase 3 trials evaluating more than 2,000 patients with moderate to severe plaque psoriasis (1-3) – In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year

AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology

NORTH CHICAGO, Ill. and HOUSTON, April 30, 2018 /PRNewswire/ — AbbVie, a research-based global biopharmaceutical company, and Rice University today announced they have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. The research at the Accelerator will focus on synthesizing novel cytotoxic